Also known as: Seagen
Seagen was a biotechnology company focused on developing and commercializing antibody-based therapies for cancer. Before being acquired by Pfizer, it marketed ADCETRIS, PADCEV, TUKYSA, and TIVDAK and maintained a pipeline of oncology programs.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.
